Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
NA-Semax Amidate7 residuesMEHFPGPEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: NA-Semax, N-Acetyl Semax Amidate, NASA (informal community abbreviation)
A single intranasal spray triggers a 3-fold increase in BDNF mRNA in the hippocampus, based on rodent data from the parent compound Semax [1]. NA-Semax Amidate (N-Acetyl Semax Amidate) is the stabilized, higher-potency version of Russia's approved nootropic peptide. No human clinical trials exist for this specific modification. The cognitive benefits persist 1 to 3 weeks after you stop dosing, which is why cycles run just 10 to 20 days. Nootropic users who want sharper focus, better verbal fluency, and sustained BDNF elevation without daily long-term dosing tend to reach for this one.
NA-Semax Amidate (N-Acetyl Semax Amidate, CAS pending) is a stabilized derivative of Semax with an estimated 3 to 5 times greater potency per microgram. Dolotov and colleagues showed the parent compound Semax produced a three-fold BDNF mRNA increase from a single dose in rat hippocampus [1], and NA-Semax Amidate pushes the pharmacokinetics further. The modification is straightforward. An N-terminal acetyl group blocks aminopeptidase degradation. A C-terminal amide cap blocks carboxypeptidase attack. The core sequence, ACTH(4-10) extended with Pro-Gly-Pro, stays identical to the parent compound approved in Russia for cognitive and neuroprotective indications. The result is a peptide that resists enzymatic breakdown in neural tissue longer than standard Semax, translating to an estimated 3 to 5 times greater potency per microgram. In practice, experienced nootropic users dose 100 to 300 mcg intranasally each morning for 10 to 20 day cycles. The peptide activates melanocortin receptors (MC3R, MC4R) and upregulates both BDNF and NGF in the basal forebrain. It also modulates serotonergic, dopaminergic, and enkephalin signaling pathways. Community reports across roughly 50 to 100 Reddit threads describe improved verbal fluency, working memory, and stress resilience within the first few days, with peak cognitive effects by days 7 to 10. The honest picture: zero human clinical trials exist for NA-Semax Amidate specifically. Every mechanistic citation traces back to the parent compound. PubMed returns about 12 results for "N-acetyl Semax" compared to roughly 150 for standard Semax. The potency multiplier is a pharmacokinetic inference, not a validated human comparison. Community experience across users who dose correctly has been consistently positive, but this is a preclinical compound with community-derived dosing.
NA-Semax Amidate is a synthetic analog of ACTH(4-10) extended with a Pro-Gly-Pro tripeptide tail. It activates melanocortin receptors MC3R and MC4R in the brain without triggering adrenal cortisol release, which separates it from full-length ACTH. The primary neurotrophic action comes through BDNF upregulation. Dolotov and colleagues showed that a single application of Semax at 50 mcg/kg produced a 1.4-fold increase in BDNF protein and a 3-fold increase in exon III BDNF mRNA in the hippocampus [1]. TrkB receptor phosphorylation increased 1.6-fold in the same study. A separate group confirmed that Semax raises NGF levels in the basal forebrain [2]. Beyond neurotrophins, the peptide modulates serotonergic, dopaminergic, and enkephalin (opioid) signaling systems. This multi-pathway engagement likely explains the combined cognitive and mood effects that community users consistently describe. The N-acetyl and amide modifications don't change receptor binding. They increase resistance to aminopeptidase and carboxypeptidase degradation. Vlasov and colleagues examined the influence of N-terminus acetylation on Semax biological activity directly [3]; this is the only peer-reviewed study on the specific modification. The practical effect is extended duration of activity in neural tissue compared to the parent compound.
No human clinical trials exist for NA-Semax Amidate specifically. All mechanistic evidence derives from the parent compound Semax: approved in Russia for cognitive/neuroprotective indications and studied in human ischemia settings. The N-acetyl + C-terminal amide modifications are pharmacokinetically rational (protease resistance, extended intraneural duration) but unstudied in humans as a distinct compound. The 3–5× potency multiplier cited in peptides.ts is a pharmacokinetic inference, not a formally validated human potency comparison.
Dolotov et al. 2006 (PMID 16996037): Semax produces 3-fold BDNF mRNA increase and 1.6-fold TrkB phosphorylation in rat hippocampus at 50 mcg/kg (parent compound, not NA-Semax Amidate). For acetylation modification directly. Vlasov et al. 2016 (PMID 27586814), "Influence of N-terminus acetylation of Semax peptide on its biological activity," is the only peer-reviewed study examining the modification; absent from peptides.ts references.
No human RCTs for NA-Semax Amidate. PubMed count ~12 for "N-acetyl Semax" vs ~150 for parent Semax: extreme evidence gap for the modified form. All four references in peptides.ts are for parent Semax, not the amidate form. Potency multiplier (3–5×) is a community estimate from pharmacokinetic reasoning, not a controlled human comparison. researchStatus correctly tagged preclinical.
Positive but niche. Experienced nootropic users consistently report clear cognitive enhancement and mood stabilization at appropriate doses. Community consensus: superior duration and smoother profile than standard Semax at corrected dose. The #1 failure mode is treating it as equivalent-dose to parent Semax due to the 3–5× potency difference.
Community dosing, cycling rationale (10–20 day cycles), and route preference (intranasal) align with the Russian Semax clinical protocol tradition. Reported mechanism (BDNF upregulation, cognitive enhancement, neuroprotection) matches the validated parent compound mechanism. Divergent on the potency multiplier: community consensus of 3–5× is pharmacokinetically reasonable but not formally validated in humans. Science has no direct human data for NA-Semax Amidate; all parent-compound endorsement is inferred across the modification.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 100mcg | Daily |
| Moderate | 300mcg | Daily |
| Aggressive | 600mcg | Daily |
Start at 100 mcg intranasal, period. The potency mismatch with standard Semax is the number one user error. If you were running Semax at 300 mcg, your starting dose here is 100 mcg. Reconstitution math for intranasal: 10 mg vial plus 10 mL bacteriostatic water gives you 1 mg/mL (1000 mcg/mL). A standard nasal atomizer delivers about 0.1 mL per actuation, so each spray is 100 mcg. Three sprays gets you 300 mcg. Split across nostrils, wait 5 minutes between sides. For subcutaneous (less common): 10 mg vial plus 4 mL bacteriostatic water gives you 2.5 mg/mL. On a U-100 insulin syringe, 100 mcg is 4 IU, 300 mcg is 12 IU, 600 mcg is 24 IU. Dose before 10 AM. Nothing after 1 PM. The dopaminergic tail will wreck your sleep if you dose late. Refrigerate the reconstituted spray at 2 to 8 degrees C and toss it after 30 days. Buy lyophilized vials over pre-mixed sprays; they survive shipping better.
Standard protocol is 10-20 days on, 10-20 days off. Cognitive benefits often persist during the off period due to sustained BDNF elevation. Some users run 30-day cycles with longer breaks.
Primary rationale from the original Russian Semax clinical protocols: cycling prevents melanocortin receptor (MC3R/MC4R) desensitization with sustained agonist exposure. Secondary: BDNF and NGF upregulation reaches a plateau within 10–20 days, making continued dosing yield diminishing returns while the neurotrophic benefits persist post-cessation: the off-period is a productive continuation of the effect, not a gap. Community users also cite a "fresh response" upon returning after the off-period as empirical evidence of receptor resensitization.
Or use the universal Peptide Calculator for any peptide.
Expected: Improved focus, verbal fluency, and working memory within days 1–3. Mood stabilization by end of week 1. Cognitive benefits typically persist 1–2 weeks post-cycle.
Monitor: Track anxiety and sleep quality daily. Reduce or skip dose if waking earlier than baseline or noticing irritability building over consecutive days.
Add 10 mL of bacteriostatic water to a 10 mg NA-Semax Amidate vial. This gives you 1 mg/mL (1000 mcg/mL). Swirl gently, do not shake. Let the powder dissolve fully.
Transfer the reconstituted solution into a calibrated nasal atomizer (0.1 mL per actuation). Each spray delivers 100 mcg.
A gentle saline rinse before dosing reduces irritation and improves absorption.
Tilt your head slightly forward. Insert the spray tip into one nostril while closing the other. Press once and inhale gently. If your target dose is 200 mcg or higher, wait 5 minutes, then spray the other nostril.
Dose in the morning, ideally before 10 AM. Do not dose after 1 PM. The stimulatory effects last 6 to 12 hours.
Refrigerate the reconstituted spray at 2 to 8 degrees C. Discard after 30 days. Keep lyophilized (unreconstituted) vials at room temperature for up to 30 days, refrigerated for up to 24 months.
For subcutaneous injection (alternative route): reconstitute 10 mg in 4 mL bacteriostatic water for 2.5 mg/mL. Use a 29 to 31 gauge insulin syringe. 100 mcg equals 4 IU on a U-100 syringe. Inject into abdominal subcutaneous fat, rotate sites. Expect onset in 30 to 45 minutes versus 5 to 15 minutes intranasal.
Reference standard for all community dosing. Estimated intranasal bioavailability to CNS: 30–50% (improved over standard Semax due to amide cap; some sources cite up to 60%). Onset 5–15 min.
Reconstitute 10 mg vial in 10 mL BAC water = 1 mg/mL. Standard nasal atomizer at ~0.1 mL/actuation = 100 mcg per spray. Store reconstituted spray refrigerated at 2–8°C; discard after 30 days.
Same mcg dosing as intranasal (no established dose adjustment). Onset ~30–45 min vs 5–15 min intranasal. Lower estimated CNS bioavailability per dose but more precise volumetric administration.
Reconstitute 10 mg vial in 4 mL BAC water = 2.5 mg/mL (2500 mcg/mL). Inject into abdominal subcutaneous fat; rotate sites. U-100 insulin syringe units: 100 mcg = 4 IU, 300 mcg = 12 IU, 600 mcg = 24 IU.
Complementary mechanism: Selank is GABAergic and anxiolytic; counters the stimulatory/dopaminergic profile of NA-Semax Amidate. Community describes the combination as "cognitive clarity + calm." The most frequently cited NA-Semax Amidate stack. Both are intranasal, allowing co-administration.
NA-Semax Amidate 100–300 mcg intranasal AM + Selank 250–500 mcg intranasal AM or midday. Can co-administer or stagger by 30 min.
Dopaminergic baseline support: Bromantane raises dopamine synthesis via tyrosine hydroxylase upregulation. Community stacks for enhanced motivational drive alongside BDNF/cognitive effects of NA-Semax Amidate. Monitor for additive stimulation.
NA-Semax Amidate 100–300 mcg intranasal AM + Bromantane 50–100 mg oral AM. Avoid if prone to anxiety.
Complementary neurotrophic axes: Dihexa targets HGF/c-Met pathway for synaptogenesis; NA-Semax Amidate targets BDNF/ACTH pathway. Community stacks for broader neurotrophic coverage. Both are research-only with no human safety data for the combination.
Dihexa 5–10 mg/day oral + NA-Semax Amidate 100–300 mcg intranasal AM. Run concurrent cycles (14–20 days on, 14–20 days off).
Cholinergic support: community adds Alpha-GPC to support acetylcholine availability when BDNF-driven synaptic demand increases and to prevent headache patterns sometimes associated with increased synaptic activity. No pharmacological conflict with NA-Semax Amidate.
Alpha-GPC 300 mg oral AM, taken 30 min before intranasal NA-Semax Amidate.
NA-Semax Amidate upregulates serotonergic and dopaminergic signaling. Combining with MAOIs risks excessive monoamine accumulation and potential serotonin syndrome. Listed in peptides.ts drugInteractions.
Do not combineAdditive CNS stimulation from overlapping dopaminergic upregulation. Substantially increases risk of anxiety, agitation, cardiovascular stress, and insomnia. Listed in peptides.ts drugInteractions.
Parent compound Semax influences vascular gene expression (PMID 24661604). Precautionary: no direct interaction data for NA-Semax Amidate specifically.
Pricing updated 2026-04-09
Overstimulation is the most reported problem with NA-Semax Amidate, and it is almost always self-inflicted. The compound is 3 to 5 times more potent per microgram than standard Semax. Users who transfer their parent compound dose directly (e.g. 300 mcg Semax mapped straight to 300 mcg NA-Semax Amidate) experience anxiety, agitation, and irritability. This is the number one failure mode cited across community reports. The anxiety response deserves emphasis. NA-Semax Amidate upregulates dopaminergic and serotonergic signaling. At higher doses, that stimulation tips from productive focus into agitation. Users with a history of anxiety disorders face increased risk; this compound is listed as contraindicated for severe anxiety disorders for exactly this reason. If anxiety appears, drop to 100 mcg and dose before 10 AM. Resolution typically happens within 1 to 2 days at the reduced dose. Sleep disruption ranks second among community complaints. The dopaminergic upregulation has a 6 to 12 hour activity tail. Dosing after 1 PM is the primary cause. Shifting the dose earlier in the morning typically resolves sleep disruption within 2 to 3 days. Hair thinning has been reported at sustained doses above 300 mcg per day over 30 or more days. The speculated mechanism involves melanocortin receptor (MC4R) activity. No clinical documentation exists for this effect; community reports indicate it reverses after cessation. The reports are rare. Nasal irritation can occur with intranasal use. Reconstituting above 2.5 mg/mL concentration increases irritation risk. Using a saline rinse before dosing helps. If irritation persists, subcutaneous injection is an alternative route. The human safety dataset is extremely limited. All published data comes from the parent compound Semax, not the amidate modification. PubMed returns about 12 results for the modified form. The researchStatus is correctly tagged as preclinical. No formal adverse event reporting exists. Contraindications include pregnancy, breastfeeding, known hypersensitivity to Semax or ACTH-derived peptides, active bleeding disorders, and history of severe anxiety disorders. If combining with MAO inhibitors, the risk of excessive monoamine accumulation and serotonin syndrome is real; that combination should be avoided. Stimulant medications (amphetamines, methylphenidate) carry additive CNS stimulation risk. Anticoagulant users should monitor closely given Semax's documented influence on vascular gene expression [4]. Stop use and consult a physician if new anxiety disorder symptoms appear, if insomnia persists despite timing adjustments, or if blood pressure exceeds 140/90 mmHg.
Verify NA-Semax Amidate dosing and safety with a second opinion
Research-only compound with no FDA manufacturing oversight. Smaller market volume vs mainstream peptides means fewer vendors and less competitive quality pressure. Intranasal formulations require sterility and endotoxin standards that not all research vendors meet. No large-scale independent purity testing data exists for this compound.
| Test | When | Target |
|---|---|---|
| Blood pressure | Baseline before first dose; mid-cycle (day 7); any time symptoms arise | <130/80 mmHg at rest; hold dose and evaluate if >140/90 mmHg |
| Anxiety and mood self-assessment | Daily during cycle | Any new or worsening anxiety disorder symptoms, persistent irritability, or insomnia → reduce dose or discontinue |
| Sleep quality log | Nightly throughout cycle | Sleep onset within 30 min of personal baseline; no significant early waking |
Melanocortin receptor (MC3R/MC4R) activation may influence vascular tone. Uncontrolled hypertension is a gap in peptides.ts contraindications: flagged in verification JSON; it is listed as a contraindication for parent Semax.
Overstimulation is the primary dose-limiting side effect. Daily tracking prevents normalization of gradually escalating anxiety over multiple dosing days.
Sleep disruption from late dosing is the second most common community complaint. Early detection allows timing adjustment before cumulative sleep debt develops.
Initial effects noticeable within hours of first dose: improved mental clarity, focus, and verbal fluency. Some users report mild stimulation or slight headache as the body adjusts.
Cognitive effects become more consistent. Improved working memory, sustained attention, and motivation. Mood stabilization and reduced anxiety are commonly reported.
Peak benefits during the latter half of the cycle. BDNF elevation reaches steady state. Enhanced learning capacity and stress resilience. End of standard 2-week cycle.
Cognitive benefits often persist for 1-3 weeks after stopping, likely due to sustained BDNF and NGF levels. Effects gradually return to baseline.
Days 1 to 3, acute onset. Most users notice improved mental clarity and verbal fluency within hours of the first intranasal spray. Parent compound data from Dolotov [1] shows BDNF mRNA triples in the rat hippocampus within hours of application. Some mild stimulation is normal. Occasional slight headaches during the first day or two resolve as the body adjusts. Nasal irritation can occur if the solution concentration is too high. Days 4 to 10, accumulating neurotrophic effects. This is where the cognitive response becomes steady and consistent. Working memory improves, sustained attention sharpens, and motivation picks up. Mood stabilization and stress resilience are commonly described during this window. BDNF protein elevation is sustained and building, based on Semax rodent kinetics. Anxiety or irritability during this phase almost always means the dose was escalated too quickly or timing shifted too late in the day. Days 11 to 20, peak cycle and decision point. BDNF reaches steady-state based on Russian Semax clinical protocol precedent. Subjective benefits are at their highest. Improved learning capacity and stress resilience are typical. The standard 14-day cycle ends here; some users extend to 20 days. Diminishing marginal improvement can appear, with some users noticing habituation to the focus response past day 14. Post-cycle, 1 to 3 weeks off. The off-period is productive, not empty. BDNF and NGF protein levels remain raised 1 to 2 weeks post-cessation in rodent models. Community users consistently report that cognitive benefits persist for 1 to 3 weeks after the last dose. The return to baseline is gradual rather than sudden. This persistent post-cycle benefit is the primary community rationale for cycling rather than continuous dosing.
Intranasal absorption via olfactory neuroepithelium within minutes. Parent Semax shows 3-fold BDNF mRNA increase within hours of application and TrkB phosphorylation by day 1 in rodent hippocampus (PMID 16996037). Acute melanocortin receptor binding expected from first dose.
Most users notice mental clarity, verbal fluency, and improved focus within hours of first dose. Some mild stimulation. Occasional slight headache during first 1–2 days as body adjusts.
BDNF protein elevation sustained and accumulating based on Semax rodent data. TrkB phosphorylation and NGF upregulation in basal forebrain build through this window. Serotonergic and dopaminergic pathway modulation stabilizes.
Cognitive effects become consistent and stable. Improved working memory, sustained attention, motivation, and mood. Stress resilience commonly described. Most users identify this as the most productive phase.
BDNF steady-state based on Russian Semax clinical protocol precedent. 10–20 day cycle length follows original Russian Semax clinical protocol; no direct human data defines the optimal cycle length for NA-Semax Amidate specifically.
Peak subjective benefits. Enhanced learning capacity and stress resilience. Standard 14-day cycle ends here; some users extend to 20–30 days without reported tolerance build.
BDNF and NGF protein levels remain elevated 1–2 weeks post-cessation in rodent Semax models. Structural plasticity changes, if any, may persist beyond drug clearance. N-acetyl/amide modifications extend intraneural residence time vs parent: off-period benefits may exceed those seen with standard Semax.
Cognitive benefits persist for 1–3 weeks post-cycle. Gradual return to baseline rather than a sharp drop-off. The persistent benefit post-cycle is the primary community rationale for the cycling protocol.
Source: Estimated from Semax PK data; acetylation/amidation extend half-life vs parent compound (~2-3 min IV)
Loading the interactive decay curve.
NA-Semax Amidate is classified as a research-only compound. It has no FDA approval, no IND application on record, and no regulatory pathway in progress in any Western jurisdiction. The parent compound Semax holds marketing authorization in Russia for cognitive and neuroprotective indications, but that approval does not extend to the N-acetyl amidated modification. In the United States, NA-Semax Amidate is available from research chemical vendors and is sold for in-vitro research purposes only. It is not approved for human use by any regulatory body. Compounding pharmacy availability does not apply to this compound. WADA status is uncertain. The parent compound Semax appears on some national anti-doping watchlists given its melanocortin receptor activity. Athletes subject to drug testing should treat this peptide as a risk. This content is for informational and educational purposes only. It does not constitute medical advice. Consult a licensed healthcare provider before using any research compound.
Peptide Schedule Research TeamReviewed Apr 20265 Citations
